Difference between revisions of "Altretamine (Hexalen)"
Jump to navigation
Jump to search
(Created page with "==General information== Class: Alkylating-like, exact mechanism unknown--can form covalent adducts with tissue macromolecules including DNA<ref name="insert">[http://us.eisai.com...") |
Warner-admin (talk | contribs) m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo") |
||
| (27 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class: Alkylating-like, exact mechanism | + | Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.<ref name="insert">[http://us.eisai.com/pdf_files/hexalen_pi.pdf Altretamine (Hexalen) package insert]</ref><ref>[[:File:Altretamine.pdf | Altretamine (Hexalen) package insert (locally hosted backup)]]</ref> |
| − | <br>Extravasation: | + | <br>Route: PO |
| + | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/hexalen-altretamine-342191 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Ovarian cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[https://chemocare.com/druginfo/altretamine.aspx Altretamine (Hexalen) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/altretamine.aspx Altretamine (Hexalen) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/altretamine-patient-drug-information Altretamine (Hexalen) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/altretamine-patient-drug-information Altretamine (Hexalen) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/altretamine-patient-drug-information Altretamine (Hexalen) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/altretamine-patient-drug-information Altretamine (Hexalen) patient drug information (UpToDate)]</ref> | ||
| − | == | + | ==History of changes in FDA indication== |
| − | + | *1990-12-26: Initial FDA approval. Indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent [[ovarian cancer]] following first-line therapy with a cisplatin and/or alkylating agent-based combination. | |
| − | + | ==History of changes in EMA indication== | |
| + | *1979-01-22: EURD | ||
| + | ==Also known as== | ||
| + | *'''Generic names:''' hexamethylmelamine, HMM | ||
| + | *'''Brand name:''' Hexalen, Hexastat | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
| + | |||
| + | [[Category:Alkylating agents]] | ||
| + | [[Category:Ovarian cancer medications]] | ||
| + | |||
| + | [[Category:FDA approved in 1990]] | ||
| + | [[Category:EMA approved in 1979]] | ||
Latest revision as of 23:20, 2 September 2023
General information
Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Altretamine (Hexalen) patient drug information (Chemocare)[3]
- Altretamine (Hexalen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1990-12-26: Initial FDA approval. Indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
History of changes in EMA indication
- 1979-01-22: EURD
Also known as
- Generic names: hexamethylmelamine, HMM
- Brand name: Hexalen, Hexastat